

---

**FOR IMMEDIATE RELEASE**

**Powder Pharmaceuticals Appointed  
Two Members to Join the Board of Directors**

Hong Kong, April 8, 2013 – Lee's Pharmaceutical Holdings Limited ("the Group") (Main Board Stock Code: 0950; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has appointed Dr. Hoyoung Huh and Mr. Victor Tsui to join the Powder Pharmaceuticals board of directors on 22<sup>nd</sup> March 2013.

Dr. Hoyoung Huh graduated from Cornell University with M.D., Ph.D. Dr. Huh is experienced board of director, and currently sitting in the boards of Geron Corporation (Menlo Park, CA), Addex Pharmaceuticals (Geneva, CH), Cytomx Therapeutics (South San Francisco, CA), Stempar Sciences (San Francisco, CA), Antriabio (Menlo Park, CA) and EOS, S.p.A. (Milan, Italy). Dr. Huh is the co-founder and the managing director of Konus Advisory Group based in Menlo Park, CA.

Mr. Victor Tsui is a licensed professional engineer in the State of California, US. He graduated from The Hong Kong Polytechnics University and University of Wisconsin with a master degree in Engineering. Before joining PPI, he worked for various pharmaceuticals companies in various manufacturing capacity for over 20 years in the US. He is the co-founder and the Chief Operating Officer of PPI since its inception.

"It is excited to have both Dr. Huh and Mr. Tsui joint our board. PPI is in a critical junction of its development. With his distinguished track record in creating and nurturing successful biotech venture, Dr. Huh could help PPI's effort to make the leap to the next level. Both new members will also bring professionalism to PPI, facilitating the development of Zingo<sup>TM</sup>," commented by Dr. Benjamin Li, CEO of PPI.

**About PPI**

Powder Pharmaceuticals Inc. is a privately held company based in Hong Kong that is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder Pharmaceuticals intends to supply Zingo<sup>TM</sup> globally through international business partners. PPI has submitted the amendment with the U.S. FDA for approval of the production of Zingo<sup>TM</sup> in the new Hong Kong manufacturing facility since 29<sup>th</sup> October 2012. The submission is being reviewed by FDA and Hong Kong manufacturing facility has been inspected by FDA investigators in the end of January 2013.

### **About Lee's**

Lee's Pharmaceutical Holdings Limited is a research-based biopharmaceutical company listed in Hong Kong with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at [www.leespharm.com](http://www.leespharm.com).

### **Safe Harbor Statement**

*The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*